Effects of Contrast Strength Training in Badminton Players

May 21, 2025 updated by: Riphah International University

Effects of Contrast Strength Training on Agility, Power and Explosive Speed in Badminton Players

Badminton is one of the most popular sports worldwide. In general, badminton jumping actions have two goals: achieve maximum height and reach a precise location using certain body movements. Both objectives are important in badminton and must be considered when conducting practical training sessions and imparting techniques. The players should have agility to move on the court forward sideward and backward to do many actions with high speed. They require sports specific training to achieve power, stability and agility in the ground for a powerful performance. Contrast strength training is multi-intervention programs and it has a certain influence on agility, power and speed. A sample size of 48 badminton players from Pakistan Sports Board, university level and badminton club players will be taken through Non-Probability Convenience Sampling technique. Sample size of players with age group between 17-28 years will be taken. Players will be selected on the basis of inclusion and exclusion criteria and will be equally divided into two groups by random number generator table. Group A experimental group will perform contrast strength training. Group B participants of the control group will follow their standard badminton practice over the same duration with no strength training design. Before and after completion of the respective training agility and power will be assessed through t-test and vertical jump test. For explosive speed 40-yard dash will be performed. Data will be analyzed by using Statistical Package for the Social Sciences (SPSS) for Windows Version 25.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study aims to examine the effects of contrast strength training on agility, power, and speed in badminton players. Data will be analyzed using the Statistical Package for the Social Sciences (SPSS), version 25

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
48

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan
        • Pakistan Sports Board Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • • Both male and female athletes.

    • Participants between the age of 17-28.(10)
    • Have been playing on a regular basis three-four times a week(21)
    • Players must have been playing badminton for more than 2 years.(22)

Exclusion Criteria:

  • Athletes with systemic and neuromuscular issue(1)
  • Players have musculoskeletal problem which can hinder the trainings.(10)
  • Received surgery in the three years prior to the study or had undergone rehabilitation within the past year.(1)
  • Could not commit to full participation in the study's training regimes.
  • Did not practice any training in the last six months(10)
  • History of injury in past 6 months(10)
  • Previous history of fracture, previous injury, open wounds.(10)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group A: Contrast strength Training group
24 for contrast strength training bench press, pull over, half squat and forward lunge.
Other: contrast strength training
For eight weeks players performed Contrast strength training included bench press, pull-over, half squat, and forward lunge. Each session began with a 10-minute warm-up (jogging, dynamic stretching, and basic weightlifting exercises) and ended with a 5-minute cool-down. Training was performed twice a week for 8 weeks on non-consecutive days (Tuesday and Thursday). Exercises were done using free weights at 40-80% of 1-repetition maximum, in 3-4 sets of 2-4 repetitions
No Intervention: Group B: Control Group
24 Participants of the control group will follow their badminton practice and basic skills practice over the same duration with no strength training design

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Agility T Test
Time Frame: 8 weeks
The T-test, an accurate approach with a good intra-trial reliability score was used to measure agility. The participants were told to touch the first cone with their right hand after running 9.14 meters from the starting line. They shuffled to the second cone, which was 4.57 meters to the left, then to the third, which was 9.14 meters to the right, touching it with their right hand, then reversing to the starting line after shuffling 4.57 meters to the center cone and touching it with their left
8 weeks
Vertical Jump Power Test
Time Frame: 8 weeks
The participant applies chalk to the tips of their fingers. After standing away from the wall, the individual uses both arms and legs to help project their body upwards and jumped as high as they are capable of. Attempt to touch the wall at the top of the jump. Power will be measured by Sargent Test.
8 weeks
40-Yd Speed Test
Time Frame: 8 weeks
Speed was evaluated using the 40-Yard Sprint Test, which involves completing a single maximum-effort sprint over a 40-yard distance while recording the time. The purpose of this test was to assess the participants' 40-yard sprint performance.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Muzna ShahidMunir, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 24, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 30, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 15, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 24, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 2, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 21, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RECR & AHS/24/0464

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings